
Midland Pharmaceuticals Private Limited
About Midland Pharmaceuticals Private Limited
Data last updated:
Midland Pharmaceuticals Private Limited was a private limited company based in Wadhwan, Gujarat, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 August 1987.
The company was registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ1987PTC009899.
The company had an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It was led by directors including Prakash Navinchandra Shah and Bharatkumar Chabildas Shah.
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office was at GIDC Residential Plot No. H/78, Wadhwan, Gujarat, India – 363035.
Company details
Contact details
Midland Pharmaceuticals Private Limited's registered office is in Wadhwan, Gujarat. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressGIDC Residential Plot No. H/78, Wadhwan, Gujarat, India – 363035
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Midland Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Midland Pharmaceuticals Private Limited
FY 2022 filings availableFinancial Statement Summary
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Midland Pharmaceuticals Private Limited, buy the company report.
Board of directors of Midland Pharmaceuticals Private Limited
Midland Pharmaceuticals has 5 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prakash Navinchandra Shah | Director | 17 Aug 1987 | 39 Years 2 Months | As last reported |
| Bharatkumar Chabildas Shah | Director | 17 Aug 1987 | 39 Years 2 Months | As last reported |
| Suresh Chhabildas Shah | Director | 17 Aug 1987 | 39 Years 2 Months | As last reported |
| Vijay Chhabildas Shah Also directs: Mepro Pharmaceuticals Private Limited | Director | 17 Aug 1987 | 39 Years 2 Months | As last reported |
| Rajesh Sumanlal Shah Also directs: Mepro Pharmaceuticals Private Limited, Mepromax Life Sciences Private Limited, Rushraj Enterprises LLP and 1 more | Director | 17 Aug 1987 | 39 Years 2 Months | As last reported |
Auditor
Midland Pharmaceuticals Private Limited is audited by DINESHKUMAR V SHAH & CO for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DINESHKUMAR V SHAH & CO | FY 2019 | 125102W |
Shareholding
The shareholding of Midland Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2019, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2019 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Midland Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Midland Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Midland Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Midland Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Midland Pharmaceuticals Private Limited has 6 board changes on record since 1987: 5 appointments and 1 cessation. The latest: Jashwant Shantilal Shah ceased to be Director on 22 Jun 2009.
Frequently asked questions
Midland Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Midland Pharmaceuticals was a private limited company based in Wadhwan, Gujarat, India. The company worked in drug formulation and development, within the pharma industry. It was incorporated on 17 August 1987 and is registered under CIN U24231GJ1987PTC009899. The company has been struck off by the Registrar of Companies and is no longer operational.
Midland Pharmaceuticals had 5 directors:
- Prakash Navinchandra Shah - Director
- Bharatkumar Chabildas Shah - Director
- Suresh Chhabildas Shah - Director
- Vijay Chhabildas Shah - Director
- Rajesh Sumanlal Shah - Director
The CIN (Corporate Identification Number) of Midland Pharmaceuticals is U24231GJ1987PTC009899. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Midland Pharmaceuticals is at GIDC Residential Plot No. H78, Wadhwan, Gujarat, India – 363035.
Midland Pharmaceuticals was incorporated on 17 August 1987. It is registered with the Registrar of Companies, Ahmedabad.
The latest financial statements of Midland Pharmaceuticals on record with the MCA are for the year ended 31 March 2022. Its last annual general meeting was held on 30 September 2022. Year-wise statements from 2015 are in the company report.
Midland Pharmaceuticals operated in the pharma industry, in the drug formulation and development segment. It worked in this industry before it was struck off.
Jashwant Shantilal Shah ceased to be Director on 22 Jun 2009. Bharatkumar Chabildas Shah was appointed as Director on 17 Aug 1987. Prakash Navinchandra Shah was appointed as Director on 17 Aug 1987. Midland Pharmaceuticals has 6 board changes on record in total.
The compliance status of Midland Pharmaceuticals is compliant as of 01 July 2026.

